This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit performance for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bausch Health (BHC - Free Report) reported $2.4 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 10.9%. EPS of $0.98 for the same period compares to $0.81 a year ago.
The reported revenue represents a surprise of +2.97% over the Zacks Consensus Estimate of $2.33 billion. With the consensus EPS estimate being $0.89, the EPS surprise was +10.11%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Bausch performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Bausch here>>>Revenues- Total Bausch + Lomb revenues
: $1.22 billion versus the three-analyst average estimate of $1.17 billion. The reported number represents a year-over-year change of +17.5%.Revenues- Total Bausch Health (excl. B+L)
: $1.19 billion compared to the $1.15 billion average estimate based on three analysts. The reported number represents a change of +4.9% year over year.Revenues- Diversified Products
: $251 million versus $219.78 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.1% change.Revenues- Solta Medical
: $102 million compared to the $100.05 million average estimate based on three analysts. The reported number represents a change of +15.9% year over year.Revenues- International
: $276 million versus the three-analyst average estimate of $273.70 million. The reported number represents a year-over-year change of +6.6%.Revenues- Salix
: $558 million versus the three-analyst average estimate of $560.34 million. The reported number represents a year-over-year change of +0.2%.Revenues- Product sales
: $2.38 billion versus $2.32 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.Revenues- Other revenues
: $24 million versus the two-analyst average estimate of $22.40 million. The reported number represents a year-over-year change of +14.3%.Revenues- Bausch + Lomb- Vision Care
: $697 million versus $678.30 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.Revenues- Bausch + Lomb- Surgical
: $209 million compared to the $203.03 million average estimate based on two analysts. The reported number represents a change of +7.7% year over year.Revenues- Bausch + Lomb- Ophthalmic Pharmaceuticals
: $310 million compared to the $288.39 million average estimate based on two analysts. The reported number represents a change of +58.2% year over year.Shares of Bausch have returned -15.7% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Get the latest research report on BHC - FREE